Float Short %

5.59

Margin Of Safety %

-6

Put/Call OI Ratio

0.91

EPS Next Q Diff

-0.27

EPS Last/This Y

-0.56

EPS This/Next Y

-0.04

Price

Target Price

31.21

Analyst Recom

1.85

Performance Q

0.8

Upside

-16.0%

Beta

0.66

Ticker: ACAD

18 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-01-23	ACAD	26.85	0.70	0.08	5461
2026-01-26	ACAD	26.87	0.70	0.92	5465
2026-01-27	ACAD	26.2	0.70	9.07	5478
2026-01-28	ACAD	25.63	0.73	0.67	5601
2026-01-29	ACAD	25.62	0.73	0.20	5624
2026-01-30	ACAD	25.12	0.73	1.95	5636
2026-02-02	ACAD	26.13	0.74	0.13	5684
2026-02-03	ACAD	24.75	0.67	2.55	5973
2026-02-05	ACAD	23.47	0.82	0.64	6738
2026-02-09	ACAD	23.21	0.89	0.07	7132
2026-02-10	ACAD	22.7	0.87	0.02	7161
2026-02-11	ACAD	22.46	0.87	0.14	7179
2026-02-12	ACAD	21.6	0.86	0.88	7218
2026-02-13	ACAD	22.04	0.83	3.67	7243
2026-02-17	ACAD	22.94	0.91	0.43	7698
2026-02-18	ACAD	23.18	0.91	0.69	7889
2026-02-19	ACAD	24.32	0.91	0.11	8010
2026-02-20	ACAD	23.99	0.91	0.73	8015
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

18 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-01-23	ACAD	26.86	-83.2	80.9	0.81
2026-01-26	ACAD	26.87	-83.2	86.4	0.81
2026-01-27	ACAD	26.22	-83.2	81.0	0.81
2026-01-28	ACAD	25.64	-83.2	81.4	0.81
2026-01-29	ACAD	25.69	-83.2	86.8	0.81
2026-01-30	ACAD	25.14	-83.1	81.3	0.81
2026-02-02	ACAD	26.14	-83.1	95.1	0.81
2026-02-03	ACAD	24.75	-83.4	74.5	0.81
2026-02-04	ACAD	24.23	-83.4	81.4	0.81
2026-02-05	ACAD	23.47	-83.9	79.1	0.81
2026-02-06	ACAD	23.55	-83.9	86.9	0.81
2026-02-09	ACAD	23.22	-83.9	83.1	0.81
2026-02-10	ACAD	22.70	-83.9	81.1	0.81
2026-02-11	ACAD	22.47	-83.9	83.8	0.81
2026-02-12	ACAD	21.60	-83.9	77.4	0.81
2026-02-13	ACAD	22.03	-83.9	90.7	0.81
2026-02-17	ACAD	22.94	-83.9	95.7	0.81
2026-02-18	ACAD	23.19	-83.9	88.5	0.81
2026-02-19	ACAD	24.33	-83.9	-	0.81
2026-02-20	ACAD	24.00	-83.9	-	0.81
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-01-23	ACAD	-3.76	-0.11	5.52
2026-01-26	ACAD	-3.76	-0.72	5.03
2026-01-27	ACAD	-3.76	-0.72	5.03
2026-01-28	ACAD	-3.76	-0.72	5.00
2026-01-29	ACAD	-3.76	-0.72	5.00
2026-01-30	ACAD	-3.76	-0.72	5.00
2026-02-02	ACAD	-3.76	-0.65	5.00
2026-02-03	ACAD	-3.76	-0.65	5.00
2026-02-04	ACAD	-3.76	-0.65	5.00
2026-02-05	ACAD	-3.76	-0.65	5.00
2026-02-06	ACAD	-3.76	-0.65	5.00
2026-02-09	ACAD	-3.76	-0.51	5.00
2026-02-10	ACAD	-3.76	-0.51	5.00
2026-02-11	ACAD	-4.11	-0.51	5.57
2026-02-12	ACAD	-4.11	-0.51	5.57
2026-02-13	ACAD	-4.11	-0.51	5.57
2026-02-17	ACAD	-4.11	-1.23	5.57
2026-02-18	ACAD	-4.08	-1.23	5.57
2026-02-19	ACAD	-4.08	-1.23	5.57
2026-02-20	ACAD	-2.97	-1.23	5.59
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

0.42

Avg. EPS Est. Current Quarter

0.14

Avg. EPS Est. Next Quarter

0.15

Insider Transactions

-2.97

Institutional Transactions

-1.23

Beta

0.66

Average Sales Estimate Current Quarter

293

Average Sales Estimate Next Quarter

277

Fair Value

22.49

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

-74.9

Target Price

31.21

P/E

15.43

Forward P/E

33.56

PEG

P/S

3.88

P/B

4.42

P/Free Cash Flow

20.52

EPS

1.55

Average EPS Est. Cur. Y

0.81

EPS Next Y. (Est.)

0.78

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

24.94

Relative Volume

1.64

Return on Equity vs Sector %

-0.5

Return on Equity vs Industry %

16.9

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.01

EBIT Estimation

ACADIA Pharmaceuticals Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 653

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin which completed Phase III clinical trial to treat the negative symptoms of schizophrenia; ACP-101, which completed phase III clinical trial for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 that completed phase II clinical trial for the treatment of Alzheimer's disease psychosis and Lewy Body Dementia with psychosis; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; ACP-211 that is in phase I clinical trial for the treatment of treatment-resistant depression; ACP-2591 that is in Phase I development for Rett syndrome and Fragile X syndrome; and ACP-271, a GPR88 agonist used in evaluation of neurology and is in the IND-enabling stage. The company has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

stock quote shares ACAD – ACADIA Pharmaceuticals Inc. Stock Price stock today

news today ACAD – ACADIA Pharmaceuticals Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch ACAD – ACADIA Pharmaceuticals Inc. yahoo finance google finance

stock history ACAD – ACADIA Pharmaceuticals Inc. invest stock market

stock prices ACAD premarket after hours

ticker ACAD fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: ACAD

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y